Literature DB >> 22002325

Comparison of the spread of three botulinum toxin type A preparations.

Martina Kerscher1, Susanna Roll, Andreas Becker, Walter Wigger-Alberti.   

Abstract

Botulinum toxins are frequently used in esthetics to improve the appearance of facial wrinkles. In this setting, precise localization of the neurotoxin is required to produce the desired clinical effects. Unwanted effects can occur if the neurotoxin diffuses into untargeted muscle. Therefore, a neurotoxin with low and predictable spread would be preferable for esthetic applications. The aim of this study was to investigate the spread of three approved botulinum toxin type A preparations, with and without complexing proteins, by measuring and comparing the size of the anhidrotic halos they produced following injection of equivalent doses in an identical volume into the forehead of patients. The results showed that incobotulinumtoxinA and onabotulinumtoxinA displayed comparable spread at 6 weeks (maximal area of anhidrosis within 6 weeks) and area under the effect curve (AUEC) over 6 months. However, abobotulinumtoxinA, when assuming a 1:2.5 injection volume ratio, produced a statistically significantly greater maximal area of anhidrosis within 6 weeks and AUEC over 6 months compared with incobotulinumtoxinA. All preparations were well tolerated. The results of this study demonstrate that incobotulinumtoxinA and onabotulinumtoxinA have comparable spread, while abobotulinumtoxinA has significantly greater spread than incobotulinumtoxinA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002325     DOI: 10.1007/s00403-011-1179-z

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  14 in total

1.  Neuromodulator threading: revisiting an approach to neurotoxin delivery.

Authors:  H William Higgins; Kachiu C Lee; Yoash Enzer
Journal:  J Clin Aesthet Dermatol       Date:  2014-06

2.  Evaluating the Effect of Incobotulinumtoxin A for Glabellar, Forehead, and Crow's Feet Lines Using A High Dilution.

Authors:  Sheila C Barbarino; Jani A J van Loghem; Cheryl M Burgess; Niamh Corduff
Journal:  J Clin Aesthet Dermatol       Date:  2021-08-01

3.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

Review 4.  Botulinum toxin type A products are not interchangeable: a review of the evidence.

Authors:  Mitchell F Brin; Charmaine James; John Maltman
Journal:  Biologics       Date:  2014-10-06

5.  Technical Considerations for Filler and Neuromodulator Refinements.

Authors:  José Raúl Montes; Anthony J Wilson; Brian L Chang; Ivona Percec
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-12-14

6.  Tailored botulinum toxin type A injections in aesthetic medicine: consensus panel recommendations for treating the forehead based on individual facial anatomy and muscle tone.

Authors:  Javier Anido; Daniel Arenas; Cristina Arruabarrena; Alfonso Domínguez-Gil; Carlos Fajardo; Mar Mira; Javier Murillo; Natalia Ribé; Helga Rivera; Sofia Ruiz Del Cueto; Helder Silvestre; Marisa Tirado
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-10-19

Review 7.  Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration.

Authors:  Mark Nestor; Glynis Ablon; Andy Pickett
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

Review 8.  The Practical Use of AbobotulinumtoxinA in Aesthetics.

Authors:  Michael A C Kane; Gary Monheit
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

Review 9.  Botulinum neurotoxin formulations: overcoming the confusion.

Authors:  Souphiyeh Samizadeh; Koenraad De Boulle
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-05-30

10.  Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines.

Authors:  Welf Prager
Journal:  Clin Pharmacol       Date:  2013-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.